Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder
The primary objective of this study is to demonstrate using polysomnography (PSG) that 10 mg
lemborexant is superior to zolpidem tartrate extended release 6.25 mg (Ambien CR®) on
objective sleep maintenance as assessed by wake after sleep onset in the second half of the
night (WASO2H) after the last 2 nights of treatment in participants 55 years and older with
Long-term Study of Lemborexant in Insomnia Disorder
The key objectives of this study are to determine, using sleep diaries, whether lemborexant
at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset,
subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.